中国医学创新
中國醫學創新
중국의학창신
MEDICAL INNOVATION OF CHINA
2013年
13期
34-36
,共3页
阿立哌唑%康复训练%精神分裂症%生活质量
阿立哌唑%康複訓練%精神分裂癥%生活質量
아립고서%강복훈련%정신분렬증%생활질량
Aripiprazole%Rehabilitation training%Schizophrenia%Quality of life
目的:探讨阿立哌唑合并康复训练对精神分裂症患者生活质量的影响.方法:将符合中国精神障碍分类与诊断标准第3版(CCMD-3)诊断标准的精神分裂症患者90例随机分为两组,分别给予阿立哌唑与氯氮平治疗,共观察8周,两组患者均予以精神康复训练.于治疗前及治疗后6个月采用阳性与阴性症状量表(PANSS)评定疗效,采用副反应量表(TESS)评定不良反应,采用世界卫生组织编制的生活质量量表(WHOQOL-100)评定生活质量.结果:阿立哌唑组及氯氮平组的显效率分别为73.3%和75.6%,两组差异无统计学意义(P>0.05);治疗后4、8周,两组PANSS量表各项因子分均较治疗前下降(P<0.05),但治疗后8周阿立哌唑组阴性症状及一般精神病理分较氯氮平组差异有统计学意义(P<0.05);阿立哌唑组不良反应发生率显著低于氯氮平组(P<0.05);治疗6个月后两组在(WHOQOL-100)量表各领域均较治疗前有统计学意义(P<0.05),但阿立哌唑组在生理领域、心理领域、社会关系领域、精神支柱、生活质量方面较氯氮平组差异有统计学意义(P<0.05).结论:阿立哌唑治疗精神分裂症疗效与氯氮平相仿,不良反应少,合并精神康复治疗可显著改善精神分裂症患者的生活质量.
目的:探討阿立哌唑閤併康複訓練對精神分裂癥患者生活質量的影響.方法:將符閤中國精神障礙分類與診斷標準第3版(CCMD-3)診斷標準的精神分裂癥患者90例隨機分為兩組,分彆給予阿立哌唑與氯氮平治療,共觀察8週,兩組患者均予以精神康複訓練.于治療前及治療後6箇月採用暘性與陰性癥狀量錶(PANSS)評定療效,採用副反應量錶(TESS)評定不良反應,採用世界衛生組織編製的生活質量量錶(WHOQOL-100)評定生活質量.結果:阿立哌唑組及氯氮平組的顯效率分彆為73.3%和75.6%,兩組差異無統計學意義(P>0.05);治療後4、8週,兩組PANSS量錶各項因子分均較治療前下降(P<0.05),但治療後8週阿立哌唑組陰性癥狀及一般精神病理分較氯氮平組差異有統計學意義(P<0.05);阿立哌唑組不良反應髮生率顯著低于氯氮平組(P<0.05);治療6箇月後兩組在(WHOQOL-100)量錶各領域均較治療前有統計學意義(P<0.05),但阿立哌唑組在生理領域、心理領域、社會關繫領域、精神支柱、生活質量方麵較氯氮平組差異有統計學意義(P<0.05).結論:阿立哌唑治療精神分裂癥療效與氯氮平相倣,不良反應少,閤併精神康複治療可顯著改善精神分裂癥患者的生活質量.
목적:탐토아립고서합병강복훈련대정신분렬증환자생활질량적영향.방법:장부합중국정신장애분류여진단표준제3판(CCMD-3)진단표준적정신분렬증환자90례수궤분위량조,분별급여아립고서여록담평치료,공관찰8주,량조환자균여이정신강복훈련.우치료전급치료후6개월채용양성여음성증상량표(PANSS)평정료효,채용부반응량표(TESS)평정불량반응,채용세계위생조직편제적생활질량량표(WHOQOL-100)평정생활질량.결과:아립고서조급록담평조적현효솔분별위73.3%화75.6%,량조차이무통계학의의(P>0.05);치료후4、8주,량조PANSS량표각항인자분균교치료전하강(P<0.05),단치료후8주아립고서조음성증상급일반정신병리분교록담평조차이유통계학의의(P<0.05);아립고서조불량반응발생솔현저저우록담평조(P<0.05);치료6개월후량조재(WHOQOL-100)량표각영역균교치료전유통계학의의(P<0.05),단아립고서조재생리영역、심리영역、사회관계영역、정신지주、생활질량방면교록담평조차이유통계학의의(P<0.05).결론:아립고서치료정신분렬증료효여록담평상방,불량반응소,합병정신강복치료가현저개선정신분렬증환자적생활질량.
Objective:To explore the effect of aripiprazole combined with rehabilitation training in patients with schizophrenia quality of life of the spirit.Method:Met the Chinese classification and diagnostic criteria of mental disorders Third Edition(CCMD-3)criteria for the diagnosis of 90 patients with schizophrenia were randomly divided into two groups,aripiprazole and clozapine in the treatment of,a total of 8 weeks,two groups were psychiatric rehabilitation training. The positive and negative symptoms scale before and after treatment(PANSS)was introduced in June to assess the efficacy,the side effects scale(TESS)assessment of adverse reactions,the WHO quality of life scale(WHOQOL-100)assessment of quality of life.Result:Aripiprazole group and clozapine group markedly effective rate were 73.3%and 75.6%,with no significant difference between two groups(P>0.05);4,8 weeks after treatment,two groups of PANSS scale scores were decreased than that before treatment(P<0.05),but after 8 weeks of treatment with aripiprazole group negative symptoms and general spirit pathology is clozapine group had significant difference(P<0.05);the incidence rate of adverse reaction of aripiprazole group was significantly lower than that in clozapine group(P<0.05);after 6 months of treatment in the two groups(WHOQOL-100)scale in all areas than before treatment was statistically significant(P<0.05),but aripiprazole group in physiological field,psychological field,the field, social relations the spiritual pillar,a lower quality of life than the clozapine group had significant difference(P<0.05).Conclusion:Aripiprazole in the treatment of schizophrenia with clozapine is similar,less adverse reaction,combined with rehabilitation therapy can significantly improve the life quality of schizophrenia patients.